Abstract: Magnetic resonance spectroscopy (MRS) offers the possibility to noninvasively quantify 2HG concentration in the brain in the clinic, thereby serving as a valuable tool for patient-stratification as well as targeted treatment monitoring. Recently, hyperpolarized magnetic resonance techniques have opened up new opportunities for metabolic imaging not possible with conventional MRS in the brain. With over 10,000-fold increase in signal-tonoise ratio (SNR), dynamic metabolic processes can be interrogated in vivo with very high specificity by hyperpolarized MRI. In the following article, we will review relevant clinical studies and practical considerations of MRS and hyperpolarized MRS, as well as discuss some promising preclinical hyperpolarization studies to interrogate real-time metabolism in IDH mutations in vivo. Around 85% of IDH1 mutations occur at codon 132 with the substitution of arginine to histidine (R132H). Wild-type (wt) IDH1/2 enzymes catalyze oxidative decarboxylation of isocitrate to a-ketoglutarate (a-KG). Mutated IDH enzymes, however, perform NADPH-dependent reduction of a-KG to R(À)-2-hydroxyglutarate (2HG), an oncometabolite whose concentration can increase over 100-fold in cancer tissues. 3, 4 Magnetic resonance spectroscopy (MRS) offers the possibility to noninvasively quantify 2HG concentration in the brain, thereby serving as a valuable tool for patient-stratification as well as targeted treatment monitoring. 5 Recently, hyperpolarized magnetic resonance techniques have opened up new opportunities for metabolic imaging not possible with conventional MRS in the brain. 5 With over 10,000-fold increase in signal-to-noise ratio (SNR), dynamic metabolic processes can be interrogated in vivo with a very high specificity by hyperpolarized MRI. In the following sections, we will review relevant clinical studies and practical considerations of MRS and hyperpolarized MRS, as well as discuss some promising preclinical hyperpolarization studies to interrogate real-time metabolism in IDH mutations in vivo.
S
ingle-allele point mutations of isocitrate dehydrogenase 1 (IDH1) and IDH 2 (IDH2) genes occur frequently in low/ intermediate-grade gliomas (around 80%, WHO grade II and III) and secondary glioblastomas (85%, WHO grade IV), constituting a distinct subtype of brain cancer with better patient prognosis. 1, 2 Around 85% of IDH1 mutations occur at codon 132 with the substitution of arginine to histidine (R132H). Wild-type (wt) IDH1/2 enzymes catalyze oxidative decarboxylation of isocitrate to a-ketoglutarate (a-KG). Mutated IDH enzymes, however, perform NADPH-dependent reduction of a-KG to R(À)-2-hydroxyglutarate (2HG), an oncometabolite whose concentration can increase over 100-fold in cancer tissues. 3, 4 Magnetic resonance spectroscopy (MRS) offers the possibility to noninvasively quantify 2HG concentration in the brain, thereby serving as a valuable tool for patient-stratification as well as targeted treatment monitoring. 5 Recently, hyperpolarized magnetic resonance techniques have opened up new opportunities for metabolic imaging not possible with conventional MRS in the brain. 5 With over 10,000-fold increase in signal-to-noise ratio (SNR), dynamic metabolic processes can be interrogated in vivo with a very high specificity by hyperpolarized MRI. In the following sections, we will review relevant clinical studies and practical considerations of MRS and hyperpolarized MRS, as well as discuss some promising preclinical hyperpolarization studies to interrogate real-time metabolism in IDH mutations in vivo.
IN VIVO 2HG DETECTION WITH MAGNETIC RESONANCE SPECTROSCOPY
2HG molecule is a J-coupled spin system with 5 nonexchangeable proton resonances at 4.02 ppm (H2), 2.25 ppm (H4, H4 0 ), and 1.9 ppm (H3, H3 0 ) at pH 7 ( Fig. 2A , Table 1 ). In vivo detection of 2HG is challenging due to spectral overlap with NAA (2.01 ppm) and glutamate/glutamine (Glu/Gln)/gamma-Aminobutyric acid (GABA) moieties (2.1 to 2.4 ppm). [6] [7] [8] [9] Current strategies for 2HG detection largely fall into 3 categories: (1) Detection of H4 with single voxel point resolved spectroscopy (PRESS) or adiabatic selective refocusing (LASER, semi-LASER), (2) Detection of H2 with spectrum editing approach such as Meshcher-Garwood PRESS (MEGA-PRESS) or MEGA-LASER, and (3) Detection of H2/H3 cross peak with 2D correlation spectroscopy (COSY). [7] [8] [9] [10] [11] Key experimental parameters and results in recent clinical studies using these methods are summarized in Table 2 .
The single voxel double spin echo (PRESS) sequence consists of a slice-selective 908 excitation pulse followed by 2 slice-selective orthogonal 1808 refocusing pulses. In conventional single-voxel MRS at a short echo time of 30 ms, the spectral overlap of much higher concentrations of glutamate (Glu, 12 mM), glutamine (Gln, 5 mM), and N-acetyl (NA, 12 mM) makes it difficult to sort out the much lower concentration of 2HG resonance at 2.25 ppm (ca. 3 to 5 mM), even with prior knowledge fitting. 12 An optimized long echo time PRESS reported by Choi et al 9 at TE ¼ 97 ms (TE1/TE2 ¼ 32/ 65 ms) minimized the contribution of Glu and Gln. Figure 1 demonstrated single voxel approach in phantoms. Choi et al 9 was able to demonstrate 100% detectability of 2HG in IDH mutations (n ¼ 30, 15 with IDH1/2 mutation). 8 Similarly, de la Fuente et al 10 conducted a study with more patients (n ¼ 89, 80 with IDH mutations) and slightly different TE1/TE2 timing (26/71 ms) highlighted the importance of voxel size selection. When the voxel size is less than 3.4 mL, sensitivity is only around 8% (2/24) but surges dramatically to 91% (20/22) after increasing the voxel size to at least 8 mL for patients with larger brain tumors. 10 By taking advantage of J-couplings, spectrum difference editing sequences can be optimized to detect specific metabolites while removing signals from unwanted, overlapping metabolites. MEGA-PRESS, for example, builds upon the PRESS sequence by augmenting the second refocusing pulse with a new pair of 180 pulses, one on each side. Due to the coupling of H2 and H3 protons of 2HG, the pair of narrow-band frequency selective 180 pulses can be first centered at From the $1.9 ppm to suppress H3 in one scan (ON case) and then subsequently centered at $7.5 ppm (OFF case, symmetric to the water peak at $4.7 ppm). The difference between the 2 scans reveals the H2 resonance at 4.02 ppm without significant interference from other metabolites ( One disadvantage of difference editing, however, is the lower signal yield (less than 50%) compared to that of PRESS sequence alone. 9 Other spectrum editing sequences such as JPRESS (TE-averaging PRESS), which is commonly used in MRS of GABA, could also be applied in the context of 2HG detection without much decrement in SNR.
To further separate out the 2HG spectra, 2-dimensional MR methods can be employed. LASER-COSY introduces a second dimension so that metabolites can be identified via less crowded cross-peaks. For 2HG, the cross peak of H2 and H3 at around 4.02/ 1.9 ppm lies in a region wherein no other metabolites from normal tissues or wild-type (wt) IDH cancer tissues resonate, thereby uniquely identifying 2HG (Figs. 2C, D). Although 2D methods have been deployed in clinical studies, they typically require longer scan times and a larger voxel size of 27 mL than that of 1D methods. 8, 10 Post-acquisition processing typically consists of properly combining data from multiple receiving channels, zero-filling, apodization, and using spectral-fitting tools to extract the concentration of 2HG and other metabolites of interest with unsuppressed water references. 6,8 -10 Table 2 lists the typical assumptions used for spectrum quantification. Alternatively, ratios of 2HG to other metabolites have been reported. The ratio of 2HG/(GluþGln) tends to be more effective than 2HG/Cr, because creatine levels vary in cancerous tissues.
PRECLINICAL HYPERPOLARIZATION TRIALS TO INTERROGATE IDH PATHWAY
In the study conducted by Chaumeil et al, 13 U87 glioblastoma (GBM) cells were transduced with a lentiviral vector expressing either wild-type (wt) or mutant (mut) IDH1 and cell lysates were prepared. The lysates were injected with hyperpolarized 13 C-labeled a-KG and scanned with 13 C MRS on an 11.7T MR spectrometer for 300 seconds. The resulting spectra showed a peak at 183.9 ppm in the IDH1-mut cell lysates, but not in the IDH1-wt cell lysates. This resonance was confirmed to be 13 
C-labeled 2-HG in complimentary 2D
1 H- 13 C MRS experiments. To demonstrate that hyperpolarized a-KG could penetrate the blood-brain barrier and be delivered to tumors before the signal decayed, U87-IDH1 mut cells and U87-IDH1-wt cells were injected orthotopically into the brains of nude rats. When the tumors reached approximately 0.4 cm 3 , the rats were injected intravenously with hyperpolarized 13 C-labeled a-KG and scanned with 13 C MRS on a 3T clinical MRI. Because of the low field strength, the a-KG and 2-HG resonances, which differ by only 0.1 ppm, could not be spectrally resolved. However, the spectra from the rats harboring IDH1-wt xenografts displayed a unimodal temporal evolution, representing only the resonance from a-KG, whereas the spectra from the rats harboring IDH1-mut xenografts displayed a bimodal temporal evolution, representing the signal decay of a-KG as well as its metabolic conversion into 2HG. The spatial distribution of the metabolites was determined with 13 C 2D chemical shift imaging (CSI) (Fig. 3) . Voxels were placed in areas with blood vessels, normal brain, and in the IDH1-wt and IDH1-mut tumors. 2-HG was only observed in the IDH1-mut tumor voxels, with an average SNR of 1.4, demonstrating the validity of this technique. The SNR could potentially be increased by employing ester derivatives of a-KG as hyperpolarization substrates, which are shown to have a greater uptake in the cell. 14 In another study performed by the same laboratory, 15 hyperpolarized 13 C-labeled a-KG was used to detect decreases in glutamate production in IDH1-mut tumors. Branched-chain amino acid transaminase 1 (BCAT1) is responsible for converting branchedchain L-amino acids into branched-chain a-keto acids while simultaneously converting a-KG into glutamate, and because the expression of the BCAT1 enzyme is significantly reduced in IDH1-mut tumors compared with IDH1-wt tumors, 16 corresponding glutamate levels were expected to be reduced. Using spectrophotometry, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) assays of IDH-wt and IDH-mut cells and xenografts, the investigators showed that BCAT1 activity, protein levels, and mRNA expression were significantly decreased in IDH1-mut cells compared with IDH-wt cells. In addition to BCAT1, the aspartate transaminase (AST) and glutamate dehydrogenase (GDH) enzymes, which help catalyze the conversion of a-KG to glutamate, were also reduced in IDH1-mut cells. In the cell lysate experiments, hyperpolarized a-KG conversion was analyzed by NMR spectroscopy and glutamate accumulation was observed at 177.5 ppm within 12 seconds in the IDH1-wt cells. However, in the IDH1-mut cells, the glutamate resonance was barely visible. This result was also seen in vivo with intracranial rat xenografts harboring the IDH1-wt and IDH1-mut cells. Using a clinical 3T MR scanner, hyperpolarized 13 C-labeled a-KG was injected intravenously and the relative glutamate concentration was measured using 13 C 2D CSI pulse sequences with voxels placed in normal brain tissue and in tumors. Twenty-five seconds after injection, glutamate was present in normal brain tissue and in the IDH1-wt tumors, but not in the IDH1-mut tumors. Taken together, the findings from these studies indicate that injection of 13 C-labeled a-KG results in increased signal of hyperpolarized 2-HG yielding positive contrast enhancement, and therefore direct confirmation of the presence of IDH1 mutations. On the contrary, injection of 13 C-labeled a-KG results in decreased signal of hyperpolarized glutamate, yielding negative enhancement, and therefore only indirect confirmation of the presence of IDH1 mutations. There are current efforts in place to simultaneously detect both the increase in 2-HG and decrease in glutamate from 1 injection of hyperpolarized a-KG.
Hyperpolarized pyruvate has also been used as an imaging agent in profiling the metabolism of IDH-mutated gliomas. 17 Several studies have monitored the conversion of hyperpolarized pyruvate to lactate in glioblastoma tumors in vivo for the purposes of diagnosis 18, 19 and treatment response. [20] [21] [22] In this work, two cell lines were studied: U87, which is a well-established glioblastoma cell line and BT142, which is a glioma cancer stem cell line derived from a patient with a WHO grade III IDH1-mutant oligoastrocytoma. Western blot analysis showed that the expression of lactate dehydrogenase A (LDHA) and monocarboxylate transporter 1 and 4 (MCT1 and MCT4) was significantly reduced in the BT142 cells compared with U87. Hyperpolarized 13 C-labeled pyruvate was injected into the medium, and the cells were collected and analyzed with 13 C MRS on an 11.7T spectrometer for 300 seconds. The metric used to measure the flux from pyruvate to lactate was the ratio of the area under the time-dependent signal curve of lactate to that of pyruvate, denoted as [ 3 in size, mice were injected intravenously with hyperpolarized 13 C-labeled pyruvate and scanned on a 14.1 T animal MRI. U87 and BT142 had similar levels of pyruvate uptake, but the BT142 tumors produced significantly less hyperpolarized lactate than did the U87 tumors. The mice harboring BT142 xenografts were then treated with Temozolomide (TMZ), which is a standard-of-care chemotherapeutic agent for glioblastoma. The size of the tumors was dramatically reduced and survival was increased significantly. However, there was no appreciable difference in [Lac]/[Pyr] over the course of treatment. Thus, due to the reduced levels of LDHA, MCT1, and MCT4, hyperpolarized pyruvate did not appear to be a good option for imaging IDH1-mutated tumors. Of course, only 1 cell line was tested and results with other lines may yield different results. This is an active area of current research and more research is needed to link genomics and metabolomics of IDH mutation with real-time metabolic imaging in brain tumor with hyperpolarization.
CONCLUSION
Multiple proton MRS techniques are in place and have been applied in the clinic for detection of 2HG and follow-up of therapy in brain tumor patients with IDH mutation. On the contrary, real-time follow-up of IDH metabolic pathway with hyperpolarized MR is relatively recent and has been only applied to animal models. However, hyperpolarized 13 C MR has been rapidly gaining acceptance in the clinic and various clinical trials in multiple organ sites, including brain, are in progress in at least 8 institutions worldwide to establish the clinical efficacy of this emerging technique. It is plausible that in vivo metabolic imaging in IDH mutation is the next frontier in brain cancer diagnosis and assessing therapeutic efficacy; with the combined knowledge of genomics, a clearer understanding of tumorigenesis in brain might be achieved.
